The CEO of a Birmingham-based cancer biotech company is slated to speak at an upcoming international convention.
Karim I. Budhwani, CEO of CerFlux Inc., will lead a panel discussion on artificial intelligence (AI) usage in cancer drug discovery at the BIO International Convention on June 5.
CerFlux Inc. is a biotech company that creates advanced personalized medicine technology for cancer research. The BIO International Convention is the largest biotech conference in the world, and will take place from June 3-6 in San Diego.
This will be Budhwani's third year consecutive year leading a panel discussion at the event. This year's topic is "The Oncology Endgame: Assemble and Shine with Precision Medicine, or Lose." The panel will include leaders from Johnson & Johnson, Alnylam and Frederick National Laboratory (FNL) for Cancer Research.
“We have in front of us a clear choice: We can either harness transformative technologies to shape the future of medicine or we can watch from the sidelines as others seize the opportunity to make a global and generational impact,” Budhwani said. “Our panel discussion is about this choice – about positioning biotech leaders to take maximum advantage of these technologies to crush cancer.”
The discussion will focus on how AI can improve cancer drug research, look at possibilities for biotech and pharmaceutical companies and address challenges so goals can be met.
“We must ensure we are utilizing all available tools in our fight against cancer, including the ever-expanding advancements in AI,” said Maggie Scully, partnership development director at Frederick National Laboratory. “Enabling partnerships and sharing AI resources will ensure rigorous and equitable application in cancer research and care.”
